The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | Patient risk stratification in MPNs: current and future approaches
In this video, Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center, Tampa, FL, shares some insights into current and future approaches to patient risk stratification in myeloproliferative neoplasms (MPNs). Dr Kuykendall first explains how clinical factors have been commonly used when risk stratifying patients, and then goes on to discuss the importance of incorporating genetic factors and improving prognostic tools in the future. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Research fees – Morphosys, GSK
Honoraria – Incyte
